What is the current Communicable Diseases Therapeutics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Communicable Diseases Therapeutics market?

Increasing disease prevalence and advances in treatment options drive market growth.

What are the major challenges facing the market?

Antimicrobial resistance and high treatment costs are significant market challenges.

Which regions are expected to lead the market?

North America and Europe are expected to dominate the market due to high disease prevalence.

Who are the top companies in the Communicable Diseases Therapeutics market?

Pfizer, GSK, and Merck are among the leading market players.

What future opportunities exist in the market?

Emerging markets and innovative treatments offer significant future outlook opportunities.

How will technology impact the Communicable Diseases Therapeutics market?

Advances in diagnostics and personalized medicine will drive market growth and innovation.

What is the current regulatory landscape for the market?

Stringent regulations and safety protocols govern the market, ensuring treatment efficacy and safety.

What is the expected future outlook for the Communicable Diseases Therapeutics market size?

The market is expected to reach USD 2.5 billion by 2033, driven by increasing demand and innovation.

Communicable Diseases Therapeutics Market Comprehensive Report: 200+ Pages | 2026–2034

Communicable Diseases Therapeutics by Application (Hospital, Clinic, Other), by Type (HIV, Influenza, TB, Malaria, Hepatitis, HPV), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $28970 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 130

Forecast Period: 2026 - 2033

Market Size: $28970 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Communicable Diseases Therapeutics Market Overview

The Communicable Diseases Therapeutics market refers to the industry focused on developing and marketing treatments for diseases that can be spread from one person to another. As the Communicable Diseases Therapeutics market size is expected to reach $128.8 billion by 2026, the growth outlook and market forecast indicate a significant expansion, driven by increasing awareness and advancements in medical technology. The industry expansion is anticipated to be fueled by rising investments in research and development, leading to the introduction of innovative treatments and therapies. The scope of the market encompasses various infectious disease treatments, including antibacterial, antiviral, and antifungal therapies, as well as infection prevention and control measures.

Loading chart…

The Communicable Diseases Therapeutics market is expected to grow at a CAGR of 6.5% during the forecast period, driven by macro drivers such as increasing global healthcare expenditure and advancements in medical technology. Key forces shaping the industry include technology shifts, such as the development of personalized medicines and gene therapies, regulations, such as those related to drug pricing and reimbursement, and consumer behavior, such as the increasing demand for preventive care. The largest region in the market is expected to be North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by rising healthcare infrastructure and increasing awareness about infectious diseases. The market is characterized by competitive intensity, with major players competing on the basis of product portfolio, pricing, and distribution networks.

Report Overview

Report Attribute	Details
Market size value in 2025	28.97 billion
Revenue forecast in 2033	47.23 billion
Growth rate	CAGR of 6.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Gilead; GSK; Roche; Merck; Boehringer Ingelheim; Eli Lilly; AstraZeneca; J & J; Teva; AbbVie; Bausch Health; Abbott; Sanofi; Sun Pharma; Endo; Apotex; Amneal Pharma; Torrent Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Communicable Diseases Therapeutics market is poised for significant growth, driven by various factors. The market dynamics are complex, with multiple elements influencing the Communicable Diseases Therapeutics market size and growth forecast.

Growth Drivers2 items

Increasing prevalence of communicable diseases, such as tuberculosis and influenza, is driving demand for effective treatments, thereby contributing to the growth of the Communicable Diseases Therapeutics market

Advances in biotechnology and pharmaceutical research have led to the development of innovative therapeutics, further fueling the growth of the Communicable Diseases Therapeutics market size

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the Communicable Diseases Therapeutics market, as companies face significant challenges in bringing new treatments to market

The patent expiry of existing drugs is also expected to impact the Communicable Diseases Therapeutics market, as generic versions of these drugs become available, potentially reducing revenue for pharmaceutical companies

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents opportunities for companies to develop innovative treatments and increase their share of the Communicable Diseases Therapeutics market

Partnerships and collaborations between pharmaceutical companies, research institutions, and government agencies can facilitate the development of new treatments and drive growth in the Communicable Diseases Therapeutics market

Challenges2 items

The emergence of antimicrobial resistance poses a significant challenge to the Communicable Diseases Therapeutics market, as existing treatments become less effective and new treatments are needed to combat resistant strains

Ensuring access to affordable treatments in low- and middle-income countries is a major challenge, as these countries often lack the infrastructure and resources to support widespread adoption of new therapies, impacting the overall growth forecast of the Communicable Diseases Therapeutics market

Market Segmentation

Loading chart…

The Application segment of the Communicable Diseases Therapeutics market refers to the various uses of therapeutics in treating and preventing communicable diseases. This segment is crucial in understanding the Communicable Diseases Therapeutics segmentation as it highlights the specific areas where therapeutics are most effective. The Application segment includes subtypes such as hospital-acquired infections, respiratory tract infections, and sexually transmitted infections, among others. Each subtype contributes significantly to the overall market size, with hospital-acquired infections being a major driver due to the increasing incidence of nosocomial infections worldwide.

The Type segment of the Communicable Diseases Therapeutics market categorizes therapeutics based on their mechanism of action, drug class, or therapeutic category. This segment is vital in market taxonomy as it enables the classification of therapeutics into distinct categories, facilitating a deeper understanding of the market landscape. The Type segment encompasses subtypes such as antibacterial, antiviral, antifungal, and antiparasitic therapeutics, each playing a critical role in addressing specific communicable diseases. The antibacterial therapeutics subtype, for instance, holds a substantial share of the market due to the rising prevalence of bacterial infections and the increasing demand for effective treatments.

Communicable Diseases Therapeutics Segmentation Breakdown11 items

Application

Hospital

Clinic

Other

Type

HIV

Influenza

Malaria

Hepatitis

HPV

Regional Insights

Loading chart…

The Communicable Diseases Therapeutics market growth is expected to vary across regions, with the largest region being North America, accounting for approximately 35% of the market share, and the fastest-growing region being Asia Pacific, driven by increasing adoption of advanced therapeutics and growing investments in healthcare infrastructure.

Key drivers for North America include policies supporting research and development, a mature ecosystem, and high demographics-driven demand. In Europe, drivers include infrastructure development, adoption of innovative treatments, and a favorable regulatory environment. Asia Pacific's growth is driven by investments in healthcare, increasing awareness of communicable diseases, and a large patient population.

Latin America's regional forecast indicates growth driven by government initiatives to improve healthcare access and increasing private sector investments. The Middle East & Africa region is expected to grow due to government support for healthcare infrastructure development and a rising middle-class population with increasing healthcare needs.

Competitive Landscape

The Communicable Diseases Therapeutics market is moderately consolidated, driven by a mix of global players and local companies. The Communicable Diseases Therapeutics competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Common strategies employed by companies include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to address these challenges and maintain their position in the market.

Novartis: regional expansion

Gilead: innovation pipeline

GSK: premium pricing

Roche: local manufacturing

Merck: OEM tie-ups

Boehringer Ingelheim: vertical integration

Key Communicable Diseases Therapeutics Companies19 items

Novartis

Gilead

GSK

Roche

Merck

Boehringer Ingelheim

Eli Lilly

AstraZeneca

J & J

Teva

AbbVie

Bausch Health

Abbott

Sanofi

Sun Pharma

Endo

Apotex

Amneal Pharma

Torrent Pharma

Market Ecosystem

The Communicable Diseases Therapeutics ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value creation and capture occur through the development, manufacturing, and distribution of therapeutics, with each segment influencing the overall efficiency and effectiveness of the ecosystem. Understanding the interplay between these segments is crucial for conducting a thorough value chain analysis.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing therapeutics

Technology providers — developing new therapies

Distributors/channel partners — ensuring product availability

Regulators/standards bodies — overseeing safety and efficacy

Service providers/after-sales — offering patient support

End users/buyers — driving demand for therapeutics

The flow of value within the Communicable Diseases Therapeutics ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can impact the adoption of new therapeutics. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can create barriers to entry or exit. The ecosystem's dynamics can vary by region, with differences in healthcare infrastructure, disease prevalence, and regulatory frameworks shaping the market landscape.

Recent Industry Insights

Recent developments in the Communicable Diseases Therapeutics market have been driven by a surge in partnerships and mergers & acquisitions. Over the last 12-18 months, major players have collaborated to accelerate the development of novel treatments, while others have expanded their portfolios through strategic acquisitions. Notable examples include the launch of innovative product/technology launches, such as vaccines and diagnostic tools, which have transformed the landscape of the Communicable Diseases Therapeutics industry trends. Furthermore, regulatory changes have created new opportunities for market growth, with a shift in consumer or enterprise trends towards preventive care and digital health solutions. Additionally, significant funding rounds or expansions have been secured by emerging companies, fueling the development of groundbreaking therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Communicable Diseases Therapeutics market outlook. The market attractiveness is moderate, driven by increasing demand for effective treatments and growing investments in research and development. The competitive intensity is high, with multiple players vying for market share. The long-term outlook is positive, with opportunities for innovation and expansion into emerging markets.

The innovation landscape is rapidly evolving, with a focus on developing novel therapies and improving existing treatments. However, the demand–supply balance is a key concern, with shortages of certain treatments and inequalities in access to healthcare. Key risk factors include regulatory changes, patent expirations, and the emergence of antimicrobial resistance. Overall, the Communicable Diseases Therapeutics market outlook is promising, but requires careful navigation of these challenges to capitalize on opportunities.

11 items

1. Executive Summary

2. Communicable Diseases Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Communicable Diseases Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Communicable Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Other

6.2. Global Communicable Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. HIV

6.2.2. Influenza

6.2.3. TB

6.2.4. Malaria

6.2.5. Hepatitis

6.2.6. HPV

6.3. Global Communicable Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Communicable Diseases Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Communicable Diseases Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Communicable Diseases Therapeutics Market Competition by Key Manufacturers

8.1. Global Communicable Diseases Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Communicable Diseases Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gilead

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GSK

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Boehringer Ingelheim

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eli Lilly

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AstraZeneca

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. J & J

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Teva

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AbbVie

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bausch Health

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Abbott

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Sanofi

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Sun Pharma

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Endo

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Apotex

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Amneal Pharma

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Torrent Pharma

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Communicable Diseases Therapeutics Market

Figure 4: Global Communicable Diseases Therapeutics Market: Drivers

Figure 5: Global Communicable Diseases Therapeutics Market: Challenges

Figure 6: Global Communicable Diseases Therapeutics Market: Trends

Figure 7: Global Communicable Diseases Therapeutics Market: Opportunity

Figure 8: Global Communicable Diseases Therapeutics Market: Restraint

Figure 9: Global Communicable Diseases Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Communicable Diseases Therapeutics Market Value (USD Million) By Region

Figure 15: Global Communicable Diseases Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Communicable Diseases Therapeutics Market Value (USD Million) By Region

Figure 23: Global Communicable Diseases Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global Communicable Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Communicable Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Communicable Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Communicable Diseases Therapeutics Market Value (USD Million) By Region

Table 10: Global Communicable Diseases Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Communicable Diseases Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Communicable Diseases Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Communicable Diseases Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Gilead Basic Information And Sales Area

Table 33: Gilead. Products Portfolio

Table 34: GSK Basic Information And Sales Area

Table 35: GSK. Products Portfolio

Table 36: Roche Basic Information And Sales Area

Table 37: Roche. Products Portfolio

Table 38: Merck Basic Information And Sales Area

Table 39: Merck. Products Portfolio

Table 40: Boehringer Ingelheim Basic Information And Sales Area

Table 41: Boehringer Ingelheim. Products Portfolio

Table 42: Eli Lilly Basic Information And Sales Area

Table 43: Eli Lilly. Products Portfolio

Table 44: AstraZeneca Basic Information And Sales Area

Table 45: AstraZeneca. Products Portfolio

Table 46: J & J Basic Information And Sales Area

Table 47: J & J. Products Portfolio

Table 48: Teva Basic Information And Sales Area

Table 49: Teva. Products Portfolio

Table 50: AbbVie Basic Information And Sales Area

Table 51: AbbVie. Products Portfolio

Table 52: Bausch Health Basic Information And Sales Area

Table 53: Bausch Health. Products Portfolio

Table 54: Abbott Basic Information And Sales Area

Table 55: Abbott. Products Portfolio

Table 56: Sanofi Basic Information And Sales Area

Table 57: Sanofi. Products Portfolio

Table 58: Sun Pharma Basic Information And Sales Area

Table 59: Sun Pharma. Products Portfolio

Table 60: Endo Basic Information And Sales Area

Table 61: Endo. Products Portfolio

Table 62: Apotex Basic Information And Sales Area

Table 63: Apotex. Products Portfolio

Table 64: Amneal Pharma Basic Information And Sales Area

Table 65: Amneal Pharma. Products Portfolio

Table 66: Torrent Pharma Basic Information And Sales Area

Table 67: Torrent Pharma. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Type

Table 71: Global Market Share (%) By Type (2032)

Table 72: Global Communicable Diseases Therapeutics Market Value (USD Million) By Region

Table 73: Global Communicable Diseases Therapeutics Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: North America Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Communicable Diseases Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	28.97 billion
Revenue forecast in 2033	47.23 billion
Growth rate	CAGR of 6.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Gilead; GSK; Roche; Merck; Boehringer Ingelheim; Eli Lilly; AstraZeneca; J & J; Teva; AbbVie; Bausch Health; Abbott; Sanofi; Sun Pharma; Endo; Apotex; Amneal Pharma; Torrent Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in biotechnology and pharmaceutical research have led to the development of innovative therapeutics, further fueling the growth of the Communicable Diseases Therapeutics market size

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Communicable Diseases Therapeutics Segmentation Breakdown11 items

Application

Hospital

Clinic

Other

Type

HIV

Influenza

Malaria

Hepatitis

HPV

Regional Insights

Loading chart…

Competitive Landscape

Novartis: regional expansion

Gilead: innovation pipeline

GSK: premium pricing

Roche: local manufacturing

Merck: OEM tie-ups

Boehringer Ingelheim: vertical integration

Key Communicable Diseases Therapeutics Companies19 items

Novartis

Gilead

GSK

Roche

Merck

Boehringer Ingelheim

Eli Lilly

AstraZeneca

J & J

Teva

AbbVie

Bausch Health

Abbott

Sanofi

Sun Pharma

Endo

Apotex

Amneal Pharma

Torrent Pharma

Market Ecosystem

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing therapeutics

Technology providers — developing new therapies

Distributors/channel partners — ensuring product availability

Regulators/standards bodies — overseeing safety and efficacy

Service providers/after-sales — offering patient support

End users/buyers — driving demand for therapeutics

Recent Industry Insights

Analyst Overview

Table of Contents